Athersys, Inc. (ATHX) swung to a net loss for the quarter ended Mar. 31, 2017. The company has made a net loss of $5.63 million, or $ 0.06 a share in the quarter, against a net profit of $4.75 million, or $0.06 a share in the last year period. Revenue during the quarter plunged 90.49 percent to $1.47 million from $15.46 million in the previous year period.
Operating loss for the quarter was $6.40 million, compared with an operating income of $6.71 million in the previous year period.
Bokkelen, chairman & chief executive officer at Athersys. "Recent publications and presentations continue to illustrate how we might be able to extend the treatment window for stroke patients out to 36 hours with MultiStem, beyond the narrow window for treatment that exists today, and also the important biological mechanisms that our cell therapy may provide to help patients recover from a debilitating stroke event. Stroke remains the leading cause of serious disability, yet many people are still unaware of the signs and symptoms of stroke, or the need to take action right away, and we are committed to building public awareness in this area."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
